

Memorial Sloan Kettering Cancer Center



Comparison of Salvage Prostatectomy versus Salvage Ablative Therapy for Biopsy Proven Radiorecurrent Localized Prostate Cancer

June 30, 2019 Victor McPherson, MD, MSc, FRCSC Fellow, Urologic Oncology, MSKCC

*Victor McPherson¹, *Shiva M. Nair², Amy L. Tin³, Malcolm Dewar², Khurram Siddiqui², Daniel D. Sjoberg³, Andrew Vickers³, James Eastham¹, Joseph L. Chin²
*Authors contributed equally
¹Division of Urology, Memorial Sloan Kettering Cancer Center
²Division of Urology, University of Western Ontario, London Health Sciences Center
³Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center

Introduction

- Prostate Cancer
 - 21,300 new cases per annum in Canada¹
 - Localized disease primary therapy; Radical Prostatectomy vs Localized Radiation Therapy
 - 80-85%^{2,3} 5 year disease free survival following contemporary 78-79.2 Gy EBRT regimens
 - Localized recurrence no clear consensus on therapeutic modality
 - Salvage Ablation (HIFU/Cryotherapy)
 - Salvage Prostatectomy
 - Salvage Radiation

1. http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian%20cancer%20statistics/Canadian%20cancer%20statistics/Canadian%20cancer%20statistics/Canadian%20cancer%20statistics/Canadian%20cancer%20statistics/Canadian%

Cancer-Statistics-2018-EN.pdf?la=en.


2. Catton, et al., Journal of Clinical Oncology (2017).

3. Zietman, et al., JAMA (2005).



Methods; Samples/Data

- Data from two independently maintained registries was retrospectively analyzed
 - Salvage Radical Prostatectomy (SRP) at MSKCC
 - Salvage ablation (SA; Cryotherapy or HIFU) at UWO
 - An equivalence test for metastasis-free survival (MFS) was utilized for salvage cryotherapy and HIFU – there was no statistically significant difference (p=0.3) and thus these modalities were combined in the analysis.
- Total of 444 patients were available for analysis,
 - Noticeable differences in treatment groups → propensity score methodology
 - Final cohort of 378 patients with more similar:
 - Pre-salvage PSA
 - Gleason grade
 - Primary radiation treatment




Cohort: Patient Baseline Characteristics

	Cohort of Patients Available for Analysis (N=444)			Final Cohort In Analysis (N=378)		
	Radical Prostatectomy (N=234; 53%)	Ablation (N=210; 47%)	p-value*	Radical Prostatectomy (N=208; 55%)	Ablation (N=170; 45%)	p-value*
Primary Radiation Treatment			<0.0001			<0.0001
External Beam	133 (57%)	194 (92%)		131 (63%)	158 (93%)	
Brachytherapy	74 (32%)	12 (5.7%)		59 (28%)	10 (5.9%)	
Combination of	6 (2.6%)	1 (0.5%)		5 (2.4%)	1 (0.6%)	
Brachytherapy						
and External Beam						
Other	21 (9.0%)	2 (1.0%)		13 (6.3%)	1 (0.6%)	
Unknown	0 (0%)	1 (0.5%)		0 (0%)	0 (0%)	
Age at Salvage Treatment	65 (60, 69)	71 (66, 74)	<0.0001	66 (62, 69)	69 (65, 73)	< 0.0001
Hormonal Treatment Prior to	77 (33%)	89 (42%)	0.0001	71 (34%)	70 (41%)	0.2
Salvage Treatment						
Unknown	0 (0%)	39 (19%)		0 (0%)	28 (16%)	
PSA Prior to Salvage Treatment	3.7 (1.9, 6.3)	4.5 (2.8, 7.4)	0.004	4.1 (2.0, 6.4)	4.5 (2.7, 6.7)	0.089
Gleason Grade Prior to Salvage			0.0001			0.3
Treatment (Categorized)						
≤6	26 (11%)	54 (26%)		24 (12%)	24 (14%)	
7	125 (53%)	82 (39%)		110 (53%)	76 (45%)	
≥8	83 (35%)	74 (35%)		74 (36%)	70 (41%)	
Year of Salvage Treatment			<0.0001			<0.0001
1995-1999	0 (0%)	75 (36%)		0 (0%)	56 (33%)	
2000-2004	45 (19%)	72 (34%)		37 (18%)	58 (34%)	
2005-2009	104 (44%)	44 (21%)		95 (46%)	41 (24%)	
2010-2015	85 (36%)	19 (9.0%)		76 (37%)	15 (8.8%)	

* p-values based on Wilcoxon Rank Sum test for continuous variables and Fisher's exact test for categorical variables




Histogram of propensity score for patients available for analysis who underwent salvage radical prostatectomy (blue) and salvage ablation (red). (N=444)




Patients at extremes (less than 0.05 or more than 0.85) were removed from analysis.



CSS KM: Salvage Radical Prostatectomy (solid black line) and Salvage Ablation (dashed gray line).




MFS KM: Salvage Radical Prostatectomy (solid black line) and Salvage Ablation (dashed gray line).




Adjusted failure curve: Estimated probability of hormonal treatment after salvage radical prostatectomy (solid black line) and salvage ablation (dashed grey line) with propensity score at the mean

- 143 received ADT
- SA vs SRP;
 - ADT Initiation (HR, 1.42
 95% CI 0.97, 2.08, p=0.068)
- Median follow up time for patients not receiving hormonal treatment is 4.0 (IQR 2.0, 7.4) years




Limitations

- Propensity score matched analysis of two large independently maintained registries of salvage therapy for radiorecurrent prostate cancer
 - While propensity score matching based upon baseline variables was utilized to normalize cohorts for analysis(pre-salvage PSA, pre-salvage Gleason grade, and primary radiation treatment), this is an imperfect means of comparison and there may be unrecognized confounding variables
 - Time periods of treatment differed SRP more recent (37% 2010-2015 vs 8.8%)
 - Pre-treatment radiation regimens; EBRT 93% SA vs 63% SRP



Conclusion

- Propensity score matched analysis of two large independently maintained registries of salvage therapy for radiorecurrent prostate cancer
 - No statistically significant difference in CSS or MFS between SRP and SA
 - Some evidence of a lower risk of ADT in the cohort undergoing SRP
 - Does not reach conventional levels of statistical significance



Acknowledgements

Shiva M. Nair Amy L. Tin Malcolm Dewar Khurram Siddiqui Daniel D. Sjoberg Andrew Vickers James Eastham Joseph L. Chin



Questions?



Cohort; Patient Characteristics Adjusted for Propensity Score


	Final Cohort In Analysis (N=378)		
	Radical Prostatectomy (N=208; 55%)	Ablation (N=170; 45%)	p-value*
External Beam Only as Primary Radiation Treatment	76%	78%	0.5
Age at Salvage Treatment	66.7	66.8	0.9
Hormonal Treatment Prior to Salvage Treatment	37%	45%	0.2
PSA Prior to Salvage Treatment	5.2	5.2	>0.9
Gleason Grade Prior to Salvage Treatment ≥7	86%	88%	0.5

*p-values reflects difference between groups after adjusting for propensity score.



Timing of ADT

- Among the 67 Salvage RP patients who underwent ADT:
 - 21 (31.3%) had ADT between BCR and mets
 - 40 (59.7%) had ADT after BCR or mets
 - 2 (3.0%) had ADT before BCR or mets
 - 4 (6.0%) had ADT with no BCR or mets
- Among the 104 Salvage Ablation who underwent ADT:
 - ⁻ 31 (29.8%) had ADT between BCR and mets
 - 58 (54.2%) had ADT after BCR or mets
 - 9 (8.4%) had ADT before BCR or mets
 - 6 (5.6%) had ADT with no BCR or mets



Rectourethral Fistula Incidence

Utilizing the data available, we see no evidence of a statistically significant difference in rates of rectourethral fistula based on salvage treatment type (5.6% in the salvage

RP group vs 2.9% in the salvage ablation group, Fisher's exact p-value =0.2).



Baseline Cohort

- Cryotherapy 187, HIFU 87
- Exclusions:
 - ⁻ 15 patients with unknown pre-salvage PSA,
 - ⁻ 54 patients with unknown pre-salvage Gleason grade, and
 - ⁻ 6 patients with unknown time to death or metastasis,
 - Final cohort of 444 men for analysis

